☆ 4.3 Editorial Material

Spotlight on atezolizumab and its potential as an oncology agent

EXPERT REVIEW OF ANTICANCER THERAPY (2018)

Get Full Text
Add to Collection

Journal

EXPERT REVIEW OF ANTICANCER THERAPY
Volume 18, Issue 8, Pages 719-722

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/14737140.2018.1483241

Keywords

Lung cancer; urothelial cancer; checkpoint inhibitor; combination immunotherapy; anti-PD-L1; immunotherapy

Categories

Oncology

Funding

  1. NATIONAL CANCER INSTITUTE [ZIABC011896] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.